About Citryll
Targeting ETs, transforming inflammatory disease outcomes
Our science and products
Citryll’s lead asset, CIT-013, targets ETs via a dual mechanism of action, inhibiting the formation of new ETs and enhancing the clearance of existing ETs. This is achieved through selective binding to citrullinated histones. By selectively binding extracellular targets and not entering cells, CIT-013 is designed to minimize off-target effects while preserving normal cellular function. Through its dual mechanism and upstream positioning, CIT-013 has the potential to become a cornerstone therapy across multiple immune-mediated inflammatory diseases.
While many current therapies target individual cytokines or receptors, Citryll’s approach addresses a shared driver of inflammation. Citryll’s targeted approach has applications in many inflammatory diseases. Its current focus is on rheumatoid arthritis and hidradenitis suppurativa, with clinical development programs underway for both diseases. Citryll has the potential to create a new class of therapeutics for a wide range of immune-mediated inflammatory diseases.
Our team
Board of Directors
Advisory Board
Citryll investors
Citryll is supported by an international syndicate of world-class investors with a shared commitment to advancing breakthrough therapies.
Clinical trial opportunities for patients
Citryll is conducting clinical trials for CIT-013, an investigational therapy developed to address Rheumatoid Arthritis (RA) and Hidradenitis Suppurativa (HS). This clinical research seeks to understand CIT-013’s potential effectiveness, safety, and impact on patient quality of life. We expect two clinical trials to start by mid 2025.
